Page last updated: 2024-11-02

pamidronate and Hematologic Malignancies

pamidronate has been researched along with Hematologic Malignancies in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Specific treatment of cancer remains essential to prevent TIH relapse."2.41[Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001)
"Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)."1.42Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gabbert, TI1
Hoffmeister, B1
Felsenberg, D1
Lortholary, A1

Reviews

1 review available for pamidronate and Hematologic Malignancies

ArticleYear
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
    La Revue de medecine interne, 2001, Volume: 22, Issue:7

    Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog

2001

Other Studies

1 other study available for pamidronate and Hematologic Malignancies

ArticleYear
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem

2015